October 15, 2024
Samsung Biologics launches biopharmaceutical platform S-HiCon
Samsung Biologics, a contract development and manufacturing organisation (CDMO), has launched S-HiCon, a new high-concentration formulation platform designed to enhance the development and manufacturing of high-dose drugs.